HUTCHMED Combination Cuts Progression or Death Risk 44% in Phase III Trial
HUTCHMED said its ORPATHYS-TAGRISSO combination cut the risk of progression or death by 44% in a Phase III lung cancer trial.
Story updates
08:35:18 AM UTC
SquawkNews
HUTCHMED reported the Phase III SANOVO trial met its PFS primary endpoint in China: ORPATHYS plus TAGRISSO cut risk of progression or death by 44% vs TAGRISSO alone (HR 0.56) and 55% in high MET patients (HR 0.45), with encouraging OS benefit.Material DetailsContext by AI AnalystThis is a late-stag…